A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
== Mass spectrometry == In general, peptides can be identified by fragmenting them in a mass spectrometer. For example, during collision-induced dissociation peptides collide with a gas within the mass spectrometer and break into pieces at their peptide bonds. The resulting fragment ions (called b-ions and y-ions) have mass differences corresponding to the residue masses of the respective amino acids. Thus, a tandem mass spectrum contains partial information about the amino acid sequence of the peptide. The peptide sequence tag approach, developed by Matthias Wilm and Matthias Mann at the EMBL, uses this information to identify the peptide in a database. Briefly, a couple of masses are extracted from the spectrum in order to obtain the peptide sequence tag. This peptide sequence tag is a unique identifier of a specific peptide and can be used to find it in a database containing all possible peptide sequences.
Tetra Brik is a brand name for a carton package produced by the Swedish packaging company Tetra Pak. Its shape is cubic or cuboid, and it is available with or without various different caps. The Tetra Brik is the best-known and most sold package in the Tetra Pak packaging family, to the extent that Tetra Brik is sometimes mistaken for the brand name. The Tetra Brik comes in either chilled (Tetra Brik) or ambient (Tetra Brik Aseptic) package types.
=== Cellulose nanofiber plate === A bottom up approach can be used to create a high-performance bulk material with low density, high strength and toughness, and great thermal dimensional stability: cellulose nanofiber plate (CNFP). Cellulose nanofiber hydrogel is created by biosynthesis. The hydrogels can then be treated with a polymer solution or by surface modification and then are hot-pressed at 80 °C. The result is bulk material with excellent machinability. "The ultrafine nanofiber network structure in CNFP results in more extensive hydrogen bonding, the high in-plane orientation, and "three way branching points" of the microfibril networks". This structure gives CNFP its high strength by distributing stress and adding barriers to crack formation and propagation. The weak link in this structure is bond between the pressed layers which can lead to delamination. To reduce delamination, the hydrogel can be treated with silicic acid, which creates strong covalent cross-links between layers during hot pressing.
Over the years, Ferasse has resisted Eastern Bloc pressure to break with South Africa. At one point Moscow threatened to set up a rival Federation, but the Rumanians, with whom the French have long had good relationships, stood by France. Moscow tried again later by threatening to call off the France v. USSR match in Toulouse in November 1978. Once again Ferasse held firm and the Russians went to France, where they were beaten 29-7 In September 1981, South Africa was due to play the Mid-West in Chicago. To avoid protestors, they drove 77 miles to Racine and played in front of 247 spectators, winning 46–12. By the time they returned to Chicago, none of the protestors knew that the game had happened. In 1989 a World XV, sanctioned by the IRB and funded by South African Breweries, played two tests against South Africa in 1989 in celebration of the centenary of the South African Rugby Board (SARB). The Springboks won both, by 20–19 at Newlands Stadium in Cape Town and the second test 22–16 on 2 September at Ellis Park in Johannesburg .
Sources: en.wikipedia.org
== Awards == 2023 Tung-Ho Outstanding Research Award, THS Foundation 2023 16th Taiwan Outstanding Women in Science Awards, Wu Chien Shiung Education Foundation & L'ORÉAL Taiwan 2022 Outstanding Research Award, National Science and Technology Council 2022 Outstanding Research Award, National Science and Technology Council 2021 National Innovation Award 2020 Taiwan Society for Mass Spectrometry Medal 2011 Taiwan Society for Mass Spectrometry Outstanding Scholar Award 2007 Federation of Asian Chemical Societies Distinguished Young Chemists Award 2006 Chinese Chemical Society Outstanding Young Investigator Award
The Half-Life franchise has received critical praise for its in-depth fictional universe, including numerous characters who would go on to become well known in the gaming sphere. The original Half-Life introduces Gordon Freeman, a theoretical physicist working at the Black Mesa Research Facility who serves as the main silent playable protagonist for the franchise. Freeman is hired and put into stasis by the G-Man, an enigmatic and questionable businessman with capabilities and powers beyond any ordinary human being. The expansion packs to the original game introduce other protagonists and characters, such as Corporal Adrian Shephard in Half-Life: Opposing Force and Black Mesa security guard Barney Calhoun in Half-Life: Blue Shift (who reappears in the Half-Life 2 games). Half-Life 2 and the games following it introduce a new, more focused cast of characters fighting the oppressive Combine Empire. This includes Alyx Vance, a prominent member of the Resistance and the daughter of former Black Mesa scientist Eli Vance. Alyx is the protagonist of Half-Life: Alyx. The games have depicted numerous alien races and creatures, many from the Xen border world. Some of the most notable include the Vortigaunts, a highly intelligent alien race that often assists Freeman after he saves them from oppression, and headcrabs, parasitic aliens who latch on to heads and convert humans into mindless zombies, sometimes used as biological weapons.
Also in 1934, scientists Ernest Rutherford, Mark Oliphant, and Paul Harteck, produced the radioisotope tritium (hydrogen-3, 3H) by hitting deuterium with high-energy nuclei. The deuterium used in the experiment was a generous gift of heavy water from UC Berkeley physicist Gilbert N. Lewis. Bombarding deuterium produced two previously undetected isotopes, helium-3 (3He) and 3H. Rutherford and his colleagues successfully created 3H, but incorrectly assumed that 3He was the radioactive component. The work of Luis Walter Alvarez and Robert Cornog first isolated 3H and reversed Rutherford's incorrect notion. Alvarez reasoned that tritium was radioactive, but did not measure the half-life, though calculations at the time suggested >10 years. At the end of World War II, physical chemist Willard Libby detected the residual radioactivity of a tritium sample with a Geiger counter, providing a more accurate understanding of the half-life, now accepted as 12.3 years.
Sources: en.wikipedia.org
Compared to other TCAs, trimipramine is relatively safe in overdose, although it is more dangerous than the selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) but less dangerous than bupropion in cases of overdose.
=== Duration of action === The duration of action of a drug is the length of time that particular drug is effective. Duration of action is a function of several parameters including plasma half-life, the time to equilibrate between plasma and target compartments, and the off rate of the drug from its biological target.
== Presence in nonerythroid cells == Some nonerythroid cells (i.e., cells other than the red blood cell line) contain hemoglobin. In the brain, these include the A9 dopaminergic neurons in the substantia nigra, astrocytes in the cerebral cortex and hippocampus, and in all mature oligodendrocytes. It has been suggested that brain hemoglobin in these cells may enable the "storage of oxygen to provide a homeostatic mechanism in anoxic conditions, which is especially important for A9 DA neurons that have an elevated metabolism with a high requirement for energy production". It has been noted further that "A9 dopaminergic neurons may be at particular risk of anoxic degeneration since in addition to their high mitochondrial activity they are under intense oxidative stress caused by the production of hydrogen peroxide via autoxidation and/or monoamine oxidase (MAO)-mediated deamination of dopamine and the subsequent reaction of accessible ferrous iron to generate highly toxic hydroxyl radicals". This may explain the risk of degeneration of these cells in Parkinson's disease. The hemoglobin-derived iron in these cells is not the cause of the post-mortem darkness of these cells (origin of the Latin name, substantia nigra), but rather is due to neuromelanin. Outside the brain, hemoglobin has non-oxygen-carrying functions as an antioxidant and a regulator of iron metabolism in macrophages, alveolar cells, and mesangial cells in the kidney.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.